Page last updated: 2024-09-04

diquafosol and Cystic Fibrosis

diquafosol has been researched along with Cystic Fibrosis in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brunschweiger, A; Müller, CE	1
Abraham, WM; Boucher, RC; Boyer, J; Cowlen, M; Davis, CW; Dougherty, R; Jones, AC; Lang-Furr, M; Picher, M; Sabater, JR; Stutts, MJ; Yerxa, BR	1
Evans, R; Kellerman, D; Mathews, D; Shaffer, C	1
Engels, J; Gorden, J; Kellerman, D; Rossi Mospan, A; Schaberg, A; Smiley, L	1
Accurso, F; Aitken, ML; Boyle, M; Dovey, M; Gibson, R; Hamblett, N; Johnson, C; Kellerman, D; Konstan, MW; Milgram, L; Mundahl, J; Noone, PG; Ramsey, B; Retsch-Bogort, G; Rodman, D; Williams-Warren, J; Wilmott, RW; Zeitlin, P	1
Guile, SD; Ince, F; Ingall, AH; Kindon, ND; Meghani, P; Mortimore, MP	1
Kellerman, DJ	1

Reviews

5 review(s) available for diquafosol and Cystic Fibrosis

Article	Year
P2 receptors activated by uracil nucleotides--an update. Current medicinal chemistry, 2006, Volume: 13, Issue:3 Topics: Bone and Bones; Cystic Fibrosis; Dry Eye Syndromes; Humans; Hypersensitivity; Inflammation; Lung Diseases, Obstructive; Neoplasms; Nucleic Acid Conformation; Purinergic P2 Receptor Agonists; Purinergic P2 Receptor Antagonists; Uracil Nucleotides	2006
Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease. Advanced drug delivery reviews, 2002, Dec-05, Volume: 54, Issue:11 Topics: Administration, Inhalation; Animals; Clinical Trials as Topic; Cystic Fibrosis; Deoxycytosine Nucleotides; Epithelium; Humans; Mucociliary Clearance; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2Y2; Uracil Nucleotides; Uridine	2002
Denufosol: a review of studies with inhaled P2Y(2) agonists that led to Phase 3. Pulmonary pharmacology & therapeutics, 2008, Volume: 21, Issue:4 Topics: Administration, Inhalation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cystic Fibrosis; Deoxycytosine Nucleotides; Female; Forced Expiratory Volume; Humans; Male; Polyphosphates; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2Y2; Uracil Nucleotides; Uridine	2008
The medicinal chemistry of the P2 receptor family. Progress in medicinal chemistry, 2001, Volume: 38 Topics: Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Arteriosclerosis; Cloning, Molecular; Clopidogrel; Cystic Fibrosis; Humans; Ophthalmic Solutions; Polyphosphates; Receptors, Purinergic P2; Structure-Activity Relationship; Ticlopidine; Tissue Distribution; Uracil Nucleotides	2001
P2Y(2) receptor agonists: a new class of medication targeted at improved mucociliary clearance. Chest, 2002, Volume: 121, Issue:5 Suppl Topics: Animals; Anti-Asthmatic Agents; Bronchitis, Chronic; Cystic Fibrosis; Dose-Response Relationship, Drug; Humans; Mucociliary Clearance; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2Y2; Uracil Nucleotides; Uridine Triphosphate	2002

Trials

1 trial(s) available for diquafosol and Cystic Fibrosis

Article	Year
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatric pulmonology, 2001, Volume: 32, Issue:2 Topics: Adolescent; Aerosols; Child; Cough; Cystic Fibrosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Ophthalmic Solutions; Polyphosphates; Respiratory Sounds; Sputum; Uracil Nucleotides	2001

Article

Year

Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study.

Pediatric pulmonology, 2001, Volume: 32, Issue:2

Topics: Adolescent; Aerosols; Child; Cough; Cystic Fibrosis; Dose-Response Relationship, Drug; Double-Blind Method; Female; Forced Expiratory Volume; Humans; Male; Ophthalmic Solutions; Polyphosphates; Respiratory Sounds; Sputum; Uracil Nucleotides

2001

Other Studies

1 other study(ies) available for diquafosol and Cystic Fibrosis

Article	Year
Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 302, Issue:3 Topics: Animals; Astrocytoma; Brain Neoplasms; Calcium; Chlorides; Cilia; Cystic Fibrosis; Deoxycytosine Nucleotides; Epithelial Cells; Humans; In Situ Hybridization; In Vitro Techniques; Indicators and Reagents; Macaca mulatta; Mucins; Mucociliary Clearance; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y2; Reverse Transcriptase Polymerase Chain Reaction; Sheep; Tumor Cells, Cultured; Uracil Nucleotides; Uridine	2002

Article

Year

Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis.

The Journal of pharmacology and experimental therapeutics, 2002, Volume: 302, Issue:3

Topics: Animals; Astrocytoma; Brain Neoplasms; Calcium; Chlorides; Cilia; Cystic Fibrosis; Deoxycytosine Nucleotides; Epithelial Cells; Humans; In Situ Hybridization; In Vitro Techniques; Indicators and Reagents; Macaca mulatta; Mucins; Mucociliary Clearance; Ophthalmic Solutions; Polyphosphates; Purinergic P2 Receptor Agonists; Receptors, Purinergic P2; Receptors, Purinergic P2Y2; Reverse Transcriptase Polymerase Chain Reaction; Sheep; Tumor Cells, Cultured; Uracil Nucleotides; Uridine

2002